No connection

Search Results

TLSI

BEARISH
$4.6 Live
TriSalus Life Sciences, Inc. · NASDAQ
Target $9.2 (+100.0%)
$3.42 52W Range $7.95

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 21, 2026
Market cap
$282.51M
P/E
N/A
ROE
N/A
Profit margin
-86.9%
Debt/Equity
N/A
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
90%
TLSI exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -6.79, indicating negative shareholders' equity. While the company shows strong top-line revenue growth of 59.80% and high gross margins, these are offset by a devastating profit margin of -86.88% and consistent earnings misses. The stark disconnect between the 'Strong Buy' analyst consensus and the bearish insider selling by the CEO and officers suggests a high-risk speculative profile. Overall, the deterministic health indicators signal a high probability of further capital erosion or dilution.

Key Strengths

Strong YoY revenue growth of 59.80%
High gross margin of 84.57% indicating strong product pricing power
Healthy short-term liquidity with a current ratio of 2.80
Recent positive 1-month price momentum (+17.1%)
Positive Q/Q EPS growth trend despite remaining negative

Key Risks

Negative shareholders' equity (P/B of -6.79) indicating insolvency risk
Critical Piotroski F-Score (1/9) signaling fundamental weakness
Extreme negative profit margins (-86.88%)
Bearish insider sentiment with consistent selling by the CEO and officers
High volatility and long-term price decline (-53.2% over 5 years)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
19
Weak
Value
10
Future
50
Past
20
Health
15
Dividend
0
AI Verdict
High-Risk Speculative
Key drivers: Negative Equity, Piotroski F-Score 1/9, Revenue Growth, Insider Selling
Confidence
90%
Value
10/100

P/B of -6.79 indicates the company owes more than it owns.

Positives
No standout positives identified.
Watchpoints
  • Negative Price/Book ratio
  • No Graham Number available due to negative earnings
Future
50/100

Growth is present but not translating to bottom-line stability.

Positives
  • Strong revenue growth (59.8%)
  • High gross margins
Watchpoints
  • Lack of clear path to profitability
  • High burn rate
Past
20/100

Long-term trend is aggressively bearish.

Positives
  • Recent 1-month recovery
Watchpoints
  • 5-year return of -53.2%
  • Consistent earnings misses
Health
15/100

Deterministic health scores are in the 'Weak' category.

Positives
  • Current ratio of 2.80
Watchpoints
  • Piotroski F-Score 1/9
  • Negative ROA (-56.8%)
Dividend
0/100

Dividend strength is 0/100.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No capacity for dividends

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$4.6
Analyst Target
$9.2
Upside/Downside
+100.0%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for TLSI and closest competitors.

Updated 2026-04-20
TLS
TriSalus Life Sciences, Inc.
Primary
5Y
-53.2%
3Y
-55.4%
1Y
-18.3%
6M
-12.9%
1M
+17.1%
1W
+5.8%
SEN
Senseonics Holdings, Inc.
Peer
5Y
-81.7%
3Y
-46.7%
1Y
-43.6%
6M
-17.0%
1M
+6.8%
1W
+1.4%
SLP
Simulations Plus, Inc.
Peer
5Y
-76.6%
3Y
-65.8%
1Y
-56.0%
6M
-6.7%
1M
+23.6%
1W
+10.2%
SY
So-Young International Inc.
Peer
5Y
-65.4%
3Y
+13.5%
1Y
+262.5%
6M
-7.9%
1M
0.0%
1W
+7.8%
ANL
Adlai Nortye Ltd.
Peer
5Y
-47.0%
3Y
-47.0%
1Y
+247.2%
6M
+345.4%
1M
-14.4%
1W
-10.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-18.4
PEG Ratio
N/A
P/B Ratio
-6.79
P/S Ratio
6.26
EV/Revenue
6.56
EV/EBITDA
-11.25
Market Cap
$282.51M

Profitability

Profit margins and return metrics

Profit Margin -86.88%
Operating Margin -24.77%
Gross Margin 84.57%
ROE N/A
ROA -56.8%

Growth

Revenue and earnings growth rates

Revenue Growth +59.8%
Earnings Growth N/A
Q/Q Revenue Growth +59.85%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
N/A
Current Ratio
2.8
Strong
Quick Ratio
2.35
Excellent
Cash/Share
$0.33

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
86.7%
Op. Margin
-24.8%
Net Margin
-73.9%
Total Assets
$0.0B
Liabilities
$0.1B
Equity
$-0.0B
Debt/Equity
-2.04x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
102%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07
$N/A
2026-03-05
$-0.05
+61.5% surprise
2025-11-13
$-0.96
-481.8% surprise
2025-08-12
$-0.23
-2.8% surprise

Healthcare Sector Comparison

Comparing TLSI against 498 companies in the Healthcare sector (28 bullish, 153 neutral, 317 bearish)
Profit Margin
-86.88%
This Stock
vs
-15.87%
Sector Avg
+447.5% (Superior)
Revenue Growth
59.8%
This Stock
vs
137.48%
Sector Avg
-56.5% (Slower)
Current Ratio
2.8
This Stock
vs
4.66
Sector Avg
-39.8% (Weaker)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

SZELA MARY T.
Chief Executive Officer
Sell
2026-03-17
20,302 shares · $79,383
MARSHAK RICHARD
Officer
Sell
2026-03-16
3,457 shares · $14,210
COX BRYAN F
Officer
Sell
2026-03-16
3,184 shares · $13,085
DEVLIN JODI
Officer
Sell
2026-03-16
3,207 shares · $13,171
STEVENS JENNIFER
Officer
Sell
2026-03-16
3,530 shares · $14,509
VALLE WILLIAM J.
Director
Buy
2026-02-23
30,487 shares · $166,154
STANSKY MICHAEL P. CPA
Director
Buy
2026-02-23
361,098 shares · $1,967,984
SZELA MARY T.
Chief Executive Officer
Buy
2026-02-23
30,487 shares · $166,154
GORDON GARY B
Director
Buy
2026-02-23
9,756 shares · $53,170
PATIENCE DAVID
Chief Financial Officer
Buy
2026-02-23
3,657 shares · $19,931
MARSHAK RICHARD
Officer
Stock Award
2025-11-24
60,000 shares
COX BRYAN F
Officer
Stock Award
2025-11-24
40,000 shares
DEVLIN JODI
Officer
Stock Award
2025-11-24
50,000 shares
SZELA MARY T.
Chief Executive Officer
Stock Award
2025-11-24
550,000 shares
PATIENCE DAVID
Chief Financial Officer
Stock Award
2025-11-24
65,000 shares
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-04-07

TLSI likely filed this 8-K to announce its first-quarter financial results for the period ending March 31, 2026.

DEF 14A
DEF 14A
2026-03-31

TLSI filed a Definitive Proxy Statement on March 31, 2026, providing shareholders with necessary information and voting materials for an upcoming meeting.

8-K
8-K
2026-03-05

TLSI filed an 8-K on March 5, 2026, likely to announce its annual financial results.

10-K
10-K
2026-03-05

TLSI filed its annual 10-K on March 5, 2026, providing comprehensive disclosures regarding its business operations and financial condition. While specific financial metrics and risk details were not provided in the excerpts, the filing includes dedicated sections for Management's Discussion and Analysis and Risk Factors.

8-K
8-K
2026-02-20

TLSI filed an 8-K on February 20, 2026, likely to announce its fourth quarter and full-year financial results.

8-K
8-K
2026-02-09

TLSI filed an 8-K on February 9, 2026, likely to announce its fourth quarter and full year financial results.

8-K
8-K
2026-01-12
10-Q
10-Q
2025-11-13

TLSI submitted its 10-Q filing on November 13, 2025. While the document includes a dedicated section for Risk Factors under Item 1A, specific financial highlights and risk details were not provided in the available excerpt.

8-K
8-K
2025-11-13

TLSI filed an 8-K on November 13, 2025, likely to announce its third-quarter financial results.

8-K
8-K
2025-10-01
8-K
8-K
2025-08-29
8-K
8-K
2025-08-12
10-Q
10-Q
2025-08-12
8-K
8-K
2025-07-24
8-K
8-K
2025-06-23
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
STRONG_BUY
5 analysts
Canaccord Genuity
2026-03-09
Maintains
Buy Buy
Canaccord Genuity
2026-03-06
Maintains
Buy Buy
Canaccord Genuity
2025-12-17
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning TLSI from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile